Allianz Asset Management GmbH Has $101.72 Million Stock Position in Exelixis, Inc. $EXEL

Allianz Asset Management GmbH lifted its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 153.3% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,462,948 shares of the biotechnology company’s stock after acquiring an additional 1,490,520 shares during the quarter. Allianz Asset Management GmbH owned approximately 0.91% of Exelixis worth $101,720,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Peak Retirement Planning Inc. acquired a new stake in Exelixis in the third quarter worth about $2,332,000. Buck Wealth Strategies LLC boosted its stake in shares of Exelixis by 86.8% in the 3rd quarter. Buck Wealth Strategies LLC now owns 22,353 shares of the biotechnology company’s stock valued at $923,000 after purchasing an additional 10,389 shares during the last quarter. Jones Financial Companies Lllp grew its position in shares of Exelixis by 179.7% during the 3rd quarter. Jones Financial Companies Lllp now owns 9,477 shares of the biotechnology company’s stock worth $370,000 after buying an additional 6,089 shares during the period. State of Wyoming raised its stake in shares of Exelixis by 17.0% during the third quarter. State of Wyoming now owns 13,563 shares of the biotechnology company’s stock worth $560,000 after buying an additional 1,972 shares during the last quarter. Finally, TFB Advisors LLC bought a new stake in shares of Exelixis during the third quarter worth approximately $627,000. Institutional investors own 85.27% of the company’s stock.

Insider Activity at Exelixis

In related news, Director Mary C. Beckerle sold 24,622 shares of the firm’s stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $41.93, for a total transaction of $1,032,400.46. Following the sale, the director directly owned 21,380 shares in the company, valued at $896,463.40. This trade represents a 53.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Stelios Papadopoulos sold 100,000 shares of the company’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $43.55, for a total transaction of $4,355,000.00. Following the completion of the transaction, the director directly owned 1,189,228 shares of the company’s stock, valued at approximately $51,790,879.40. The trade was a 7.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 245,235 shares of company stock worth $10,490,600 over the last three months. 2.85% of the stock is currently owned by insiders.

Exelixis Price Performance

Shares of Exelixis stock opened at $42.59 on Wednesday. The company has a market capitalization of $11.42 billion, a P/E ratio of 17.97, a price-to-earnings-growth ratio of 0.77 and a beta of 0.42. The business has a 50-day moving average of $43.76 and a two-hundred day moving average of $40.98. Exelixis, Inc. has a 1 year low of $32.38 and a 1 year high of $49.62.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.10. Exelixis had a return on equity of 31.06% and a net margin of 29.63%.The business had revenue of $597.76 million for the quarter, compared to analysts’ expectations of $590.04 million. During the same quarter in the previous year, the business posted $0.47 EPS. Exelixis’s revenue for the quarter was up 10.8% on a year-over-year basis. On average, equities analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Key Exelixis News

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: U.S. FDA accepted the New Drug Application for zanzalintinib in combination with an immune checkpoint inhibitor for metastatic colorectal cancer — a regulatory acceptance increases the probability of future commercial upside if approved. Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib
• Positive Sentiment: H.C. Wainwright reiterated a Buy rating and set a $52 price target (roughly ~22% above current levels), citing multi-tumor commercial potential for zanzalintinib — analyst backing can support upward price pressure. Exelixis: Advancing Zanzalintinib Pipeline Underpins Buy Rating and $52 Target
• Positive Sentiment: Zacks highlights Exelixis as a strong momentum stock based on style scores — momentum interest can attract short-term buyers and algos. Here’s Why Exelixis (EXEL) is a Strong Momentum Stock
• Neutral Sentiment: Zacks and other outlets are debating whether Exelixis still represents value after multiyear gains — useful for longer-term investors but less likely to move near-term price. Is It Too Late To Consider Exelixis (EXEL) After Strong Multi Year Share Gains?
• Neutral Sentiment: Reported short-interest data show zero or erroneous values (likely a data glitch), so there’s no clear short-pressure signal from the report. Benzinga (short interest summary)
• Negative Sentiment: Zacks flags that Exelixis may lack the setup for an earnings beat in the upcoming report — lowered beat odds or cautious guidance could weigh on the stock around the release. Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings Growth

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on EXEL. Bank of America cut shares of Exelixis from a “neutral” rating to an “underperform” rating and set a $41.00 price objective on the stock. in a research note on Monday, January 5th. Citigroup lowered Exelixis from a “market outperform” rating to an “underperform” rating in a research report on Monday, January 5th. Oppenheimer reaffirmed a “market perform” rating and set a $36.00 price objective on shares of Exelixis in a research note on Wednesday, November 5th. Wolfe Research started coverage on Exelixis in a research note on Tuesday, November 18th. They issued a “peer perform” rating on the stock. Finally, Wells Fargo & Company reduced their target price on Exelixis from $36.00 to $30.00 and set an “equal weight” rating on the stock in a report on Tuesday, October 21st. Eleven equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Exelixis currently has a consensus rating of “Hold” and an average price target of $46.00.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.